[0006e] In another aspect of the present disclosure, there is provided a use of the hemodialysis solution disclosed herein in the manufacture of a medicament for the regular treatment of a chronic hemodialysis patient, wherein the medicament is to be administered with every hemodialysis session without causing iron overload.

[0006f] In a further aspect of the present disclosure, there is provided a hemodialysis solution disclosed herein for use in the treatment of a subject suffering from chronic kidney disease.

[0006g] In another aspect of the present disclosure, there is provided a hemodialysis solution disclosed herein for use in the treatment of a subject suffering from anemia.

[0006h] In a further aspect of the present disclosure, there is provided a hemodialysis solution disclosed herein for use in the treatment of a subject suffering from overt or functional iron deficiency.

[0006i] In a further aspect of the present disclosure, there is provided a hemodialysis solution disclosed herein for use in increasing or maintaining hemoglobin levels in a subject suffering from chronic kidney disease, anemia or overt or functional iron deficiency.

[0006j] In a another aspect of the present disclosure, there is provided a hemodialysis solution disclosed herein for use in the regular treatment of a chronic hemodialysis patient, wherein the solution is to be administered with every hemodialysis session without causing iron overload.

[0007] The present disclosure provides for methods of treating iron deficiency that reduces or eliminates the dose of an erythropoiesis stimulating agent (ESA) for achieving or maintaining target hemoglobin levels in a subject suffering from anemia comprising (a) administering to the subject a dose of a soluble ferric pyrophosphate composition (SFP) effective to increase hemoglobin levels of the subject, and (b) after SFP administration, (i) administering to the subject a dose of ESA that is at least 15% less than the dose of ESA administered prior to SFP administration, or (ii) discontinuing ESA administration. The dose of ESA may be administered via parenteral or oral delivery.

[0008] The present disclosure provides for methods of reducing or eliminating the dose of an erythropoiesis stimulating agent (ESA) for maintaining hemoglobin (Hgb) levels in a subject suffering from anemia comprising (a) administering to the subject, a dose of a soluble ferric pyrophosphate composition (SFP) effective to increase Hgb levels of the subject, and (b) after SFP administration, (i) administering to the subject a dose of ESA that

patient, wherein the medicament is to be administered with every hemodialysis session without causing iron overload.

6. The hemodialysis solution of claim 1 for use in the treatment of a subject suffering from chronic kidney disease.

7. The hemodialysis solution of claim 1 for use in the treatment of a subject suffering from anemia.

8. The hemodialysis solution of claim 1 for use in the treatment of a subject suffering from overt or functional iron deficiency.

9. The hemodialysis solution of claim 1 for use in increasing or maintaining hemoglobin levels in a subject suffering from chronic kidney disease, anemia or overt or functional iron deficiency.

10. The hemodialysis solution of claim 9, wherein the solution is effective to reduce or eliminate the need to administer an erythropoietin stimulating agent to achieve or maintain target hemoglobin levels in the subject.

11. The hemodialysis solution of claim 9 or 10, wherein the solution is effective to delay or prevent the need to administer an erythropoiesis stimulating agent to achieve or maintain target hemoglobin levels in the subject.

12. The hemodialysis solution of claim 1 for use in the regular treatment of a chronic hemodialysis patient, wherein the solution is to be administered with every hemodialysis session without causing iron overload.